| Drug General Information |
| Drug ID |
D09WHM
|
| Former ID |
DIB006442
|
| Drug Name |
DU-29894
|
| Indication |
Psychotic disorders [ICD9: 290-299; ICD10:F20-F29]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
Solvay Pharmaceuticals BV
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
[nH]1c(ccc1CN1CCN(c2c3occc3ccc2)CC1)c1ccc(cc1)F
|
| CAS Number |
CAS 115464-77-2
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 1A receptor |
Target Info |
Modulator |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001422) |
|---|
| REF 2 | A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol. 1995 Jan;39(1):7-14. |
|---|
